Analysis of the rate-limiting ketogenic enzyme HMGCS2 revealed significantly elevated expression in T2DM-NAFLD cohorts compared to NAFLD controls during the early stages of the disease (weeks 0–4). Here, HMGCS2 is linked to metabolic dysfunction-associated steatotic liver disease.